September 18, 2024

A Randomized, Double-blind, Placebo-controlled, Short-term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), in Treatment-Naïve HIV-Infected Participants

Key points are not available for this paper at this time.

To assess the antiviral activity, pharmacokinetics, and safety of MK-6186 in NNRTI-naïve, HIV-1-infected male participants.

Bookmark

Cite This Study

Schürmann et al. (Wed,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark